Free Trial

Vertex, Incyte fall; Precigen, Magnachip rise

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Friday:

Vertex Pharmaceuticals Inc., down $23.75 to $193.02.

The biotechnology company ended development of a potential treatment for a genetic condition that targets the liver.

Dave & Buster's Entertainment Inc., down $1.21 to $42.87.

Investors remained cautious about the beaten down restaurant and arcade owner, despite reporting surprisingly good first-quarter earnings.

Incyte Corp., down $4.95 to $82.58.

The biotechnology company's potential eczema cream ruxolitinib faces a delayed regulatory review.

Precigen Inc., up 34 cents to $7.33.

The biotechnology company gave investors an encouraging development update for a potential diabetes treatment.

Magnachip Semiconductor Corp., up $2.86 to $25.91.

The chipmaker, which agreed to a buyout from South Dearborn, received a bigger offer from Cornucopia Investment Partners.

Royal Caribbean Group, down 54 cents to $90.09.

The cruise line operator said two guests sharing a stateroom onboard its Celebrity Millennium tested positive for COVID-19.

MKS Instruments Inc., down $3.78 to $177.56.

The maker of analysis and processing equipment for semiconductor companies is reportedly seeking to buy Atotech.

Western Digital Corp., up $1.22 to $74.78.

The maker of hard drives for businesses and personal computers gave investors an encouraging update during a business conference.

Should You Invest $1,000 in Magnachip Semiconductor Right Now?

Before you consider Magnachip Semiconductor, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Magnachip Semiconductor wasn't on the list.

While Magnachip Semiconductor currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
MKS (MKSI)
4.5848 of 5 stars
$141.583.7%0.62%35.93Moderate Buy$130.70
Vertex Pharmaceuticals (VRTX)
4.8193 of 5 stars
$419.100.5%N/A29.96Moderate Buy$494.38
Incyte (INCY)
4.5969 of 5 stars
$86.17-1.6%N/A19.58Hold$84.79
Magnachip Semiconductor (MX)
3.3751 of 5 stars
$3.030.5%N/A-3.25Hold$5.50
Compare These Stocks  Add These Stocks to My Watchlist